(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 December 2014 (31.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/207232 A1

(51) **International Patent Classification**:
C12N 15/113 (2010.01) ***A61P 3/06*** (2006.01)
A61K 31/712 (2006.01)

(21) **International Application Number**:
PCT/EP2014/063757

(22) **International Filing Date**:
27 June 2014 (27.06.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

13174092.0	27 June 2013 (27.06.2013)	EP
13192930.9	14 November 2013 (14.11.2013)	EP
13192938.2	14 November 2013 (14.11.2013)	EP
PCT/EP2013/073858	14 November 2013 (14.11.2013)	EP
14153253.1	30 January 2014 (30.01.2014)	EP
14168331.8	14 May 2014 (14.05.2014)	EP

(71) **Applicant**: **SANTARIS PHARMA A/S** [DK/DK]; Fremtidsvej 3, DK-2970 Hørsholm (DK).

(72) **Inventors**: **ALBÆK, Nanna**; Ferskengangen 22, DK-3460 Birkeroed (DK). **HEDTJÄRN, Maj**; Kenny Drews vej 83, 2. Lejl. 1, DK-2450 Copenhagen SV (DK). **LINDHOLM, Marie**; Gerlachsgatan 6B, S-212 19 Malmö (SE). **NIELSEN, Niels Fisker**; Stengårdsvænge 134, DK-2800 Kgs. Lyngby (DK). **PETRI, Andreas**; Fremtidsvej 3, DK-2970 Hørsholm (DK). **RAVN, Jacob**; Skebyvej 5, DK-2740 Skovlunde (DK).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/207232 A1

(54) **Title**: ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9

(57) **Abstract**: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.